Article Text

PDF

Nebulised magnesium in asthma
  1. Jonathan Costello, Specialist Registrar,
  2. Marten Howes, Specialist Registrar
  1. Department of Emergency Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK; kevin.mackway-jonesman.ac.uk

    Abstract

    A short cut review was carried out to establish whether the addition of nebulised magnesium sulphate to β agonist therapy improves outcome in acute asthma. Altogether 69 papers were found using the reported search, of which five presented the best evidence to answer the clinical question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these best papers are tabulated. A clinical bottom line is stated.

    • asthma
    • magnesium

    Statistics from Altmetric.com

    Report by Jonathan Costello,Specialist RegistrarChecked by Marten Howes, Specialist Registrar

    Clinical scenario

    A known asthmatic patient is brought into the emergency department with signs consistent with acute asthma. Little improvement is noted with nebulised β agonist therapy. You wonder if adjunctive nebulised magnesium sulphate would provide any benefit.

    Three part question

    In [an adult with asthma] is [nebulised β agonist with nebulised magnesium sulphate better than nebulsed β agonist alone] at [improving airflow and reducing morbidity]?

    Search strategy

    Medline 1966-05/04 using the Ovid interface. [(Exp magnesium OR magnesium$.mp OR exp magnesium sulfate OR magnesium sul$.mp OR exp magnesium compounds OR magnesium compound$.mp) AND (nebulise$.mp OR nebulize$.mp OR vaporise$.mp OR vaporize$.mp OR inhal$.mp) AND (Exp asthma OR asthma$.mp OR exp bronchial spasm OR bronchial spasm.mp OR bronchospasm.mp)] Limit to human AND English language.

    Search outcome

    Altogether 69 articles found of which five were relevant to the original question (see table 1).

    Table 1

    Comment(s)

    Extensive evidence exists regarding efficacy of intravenous magnesium in bronchospasm reversal. Of the few studies that relate to nebulised magnesium in bronchospasm reversal, samples remain small and conflicting results regarding optimal dose magnesium and sole agent efficacy persist. It is empirically suggested such mode of magnesium delivery be considered in cases of severe asthma only.

    CLINICAL BOTTOM LINE

    There is currently insufficient evidence to support the routine addition of nebulised magnesium to standard β agonist therapy in acute asthma exacerbation.

    Report by Jonathan Costello,Specialist RegistrarChecked by Marten Howes, Specialist Registrar

    References

    View Abstract

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.